

Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19

Selin Somersan-Karakaya,^{1,a} Eleftherios Mylonakis,^{2,a} Vidya P. Menon,³ Jason C. Wells,⁴ Shazia Ali,¹ Sumathi Sivapalasingam,^{1,b} Yiping Sun,¹ Rafia Bhore,¹ Jingning Mei,¹ Jutta Miller,¹ Lisa Cupelli,¹ Andrea T. Hooper,¹ Jennifer D. Hamilton,¹ Cynthia Pan,¹ Viet Pham,¹ Yuming Zhao,¹ Romana Hosain,^{1,b} Adnan Mahmood,¹ John D. Davis,¹ Kenneth C. Turner,¹ Yunji Kim,¹ Amanda Cook,¹ Bari Kowal,¹ Yuhwen Soo,¹ A. Thomas DiCioccio,¹ Gregory P. Geba,¹ Neil Stahl,¹ Leah Lipsich,^{1,b} Ned Braunstein,¹ Gary A. Herman,¹ George D. Yancopoulos,¹ and David M. Weinreich,¹ for the COVID-19 Phase 2/3 Hospitalized Trial Team

¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Brown University, Providence, RI, USA; ³NYC Health + Hospitals/Lincoln, The Bronx, NY, USA; ⁴The Oregon Clinic, Portland, OR, USA

^aS. S-K. and E. M. contributed equally.

^bFormer employee of Regeneron Pharmaceuticals, Inc.

Correspondence to:

Selin Somersan-Karakaya, MD,

Email: selin.somersan@regeneron.com.

Abstract

Background: Hospitalized patients with COVID-19 experience high mortality rates, ranging from 10% to 30%. Combined casirivimab and imdevimab (CAS+IMD) is authorized for use in outpatients with COVID-19 and in post-exposure prophylaxis. The UK-based platform RECOVERY study reported improved survival in hospitalized seronegative patients treated with CAS+IMD; however, in most of the world, anti-spike monoclonal antibody therapy is currently not approved for hospitalized patients.

Methods: In this phase I/II/III double-blind placebo-controlled trial, patients hospitalized with COVID-19 were randomized (1:1:1) to 2.4 g or 8.0 g of CAS+IMD or placebo, and characterized at baseline for viral load and SARS-CoV-2 endogenous immune response.

Results: 1336 patients on low-flow or no supplemental oxygen were treated. The primary endpoint was met: in seronegative patients, the least squares mean difference (CAS+IMD vs placebo) for time-weighted average change from baseline viral load was $-0.28 \log_{10}$ copies/mL (95% confidence interval [CI] -0.51 to -0.05 ; $P = .0172$). The primary clinical analysis of death or mechanical ventilation from day 6 to 29 in patients with high viral load had a strong positive trend but did not reach significance. CAS+IMD numerically reduced all-cause mortality in seronegative patients through day 29 (relative risk reduction, 55.6%; 95% CI 24.2–74.0; nominal $P = .0032$). No safety concerns were noted.

Conclusions: In hospitalized patients with COVID-19 on low-flow or no oxygen, CAS+IMD treatment reduced viral load and the risk of death or mechanical

ventilation as well as all-cause mortality in the overall population, with the benefit driven by seronegative patients and no harm observed in seropositive patients.

Introduction

The clinical progression of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly variable; while many cases manifest with relatively mild symptoms, others progress to severe respiratory failure requiring supplemental oxygen and/or mechanical ventilation [1-4]. Casirivimab and imdevimab (CAS+IMD) is a monoclonal antibody combination approved or authorized for emergency use for the treatment of outpatients with mild-to-moderate COVID-19, and for post-exposure prophylaxis in the United States and other jurisdictions [5-7]. In outpatients with COVID-19, CAS+IMD reduced hospitalization or all-cause death, reduced viral load, and shortened symptom duration [8-10]. Data show that CAS+IMD is also highly effective in preventing asymptomatic as well as symptomatic COVID-19, evidenced by a single-dose subcutaneous administration showing ~80% lower risk of developing COVID-19 for household contacts living with an infected individual [11]. The totality of evidence suggests that benefit is greatest when treated early [12].

Based on the potent anti-viral activity of CAS+IMD, it was prospectively hypothesized that reducing viral burden as early as possible would also decrease morbidity and mortality associated with SARS-CoV-2 infection in hospitalized patients. In a recent open-label platform trial of hospitalized patients with COVID-19 in the United Kingdom (RECOVERY), CAS+IMD met its primary endpoint in improving overall survival in patients who had not mounted their own immune response at baseline (seronegative) by 20%, and also improved duration of hospitalization [13]. Here, we describe the final efficacy and safety results from the

first phase I/II/III double-blind placebo-controlled trial of CAS+IMD in hospitalized patients with COVID-19 on low-flow or no supplemental oxygen.

Methods

Trial Design

This was an adaptive, phase I/II/III, double-blinded, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CAS+IMD in hospitalized adult patients with COVID-19, conducted at 103 sites in the United States, Brazil, Chile, Mexico, Moldova, and Romania (NCT04426695).

Patients were enrolled in 1 of 4 cohorts based on disease severity: no supplemental oxygen (cohort 1A), low-flow oxygen (cohort 1), high-intensity oxygen (cohort 2), or mechanical ventilation (cohort 3), as described in the patient cohorts section in the appendix (**Supplementary Figure 1**). The trial proceeded through phase II for patients requiring no supplemental oxygen (cohort 1A) and phase III for patients requiring low-flow oxygen (cohort 1); together, these patients are the subject of this manuscript. As phase I/II data from patients on low-flow oxygen was previously unblinded in an interim analysis on December 22, 2020, it was not included in the phase III efficacy analyses. For patients requiring high-intensity oxygen (cohort 2) or mechanical ventilation (cohort 3), enrollment was paused early in the study based on recommendation of the independent data monitoring committee (IDMC) and data were not included due to low sample size; this is further described in the trial adaptations section of the appendix.

Patients were randomized 1:1:1 to a single intravenous dose of 2.4 g CAS+IMD (1.2 g casirivimab and 1.2 g imdevimab), 8.0 g CAS+IMD (4.0 g casirivimab and 4.0 g imdevimab), or placebo. Within each cohort, randomization was stratified by standard-of-care treatment (antiviral therapies, non-antiviral therapies; phase I/II/III) and country (phase II/III). The trial included a screening/baseline period (days –1 to

1), a hospitalization/post-discharge period, a monthly follow-up period, and an end-of-study visit (phase I day 169, phase II/III day 57; **Supplementary Figure 1**).

Patients

Patients were 18 years of age or older and hospitalized with confirmed SARS-CoV-2 within 72 h, with symptom onset ≤ 10 days from randomization. Standard-of-care treatments for COVID-19, per the investigator, were permitted. Full inclusion and exclusion criteria are presented in the appendix.

Outcome Measures

The primary virologic efficacy endpoint was the time-weighted average (TWA) daily change from baseline (day 1) viral load in nasopharyngeal samples through day 7 in the seronegative population [10]. The primary clinical efficacy endpoint was the proportion of patients who died or required mechanical ventilation from days 6 to 29 and days 1 to 29 for the high-viral load, seronegative, and overall populations, tested in a statistical hierarchy (**Supplementary Table 1**). Clinical efficacy from days 6 to 29 was included as part of the hierarchical testing strategy because several days of viral suppression in this severe population may be required before clinical impact is observed. High viral load was selected for the first clinical efficacy endpoint in the hierarchy based on previous experience with treatment in the outpatient setting [8, 10]; it was expected that the high viral load population would be highly correlated with the seronegative population, and assessing viral load could be easier than assessing serostatus in a clinical setting.

Secondary efficacy endpoints examined all-cause mortality and discharge from/readmission to hospital. Safety endpoints included the proportion of patients with treatment-emergent serious adverse events (SAEs) and adverse events of

special interest (AESIs): infusion-related reactions (IRRs) through day 4, and grade ≥ 2 hypersensitivity reactions through day 29.

Statistical Analysis

The statistical analysis plan was finalized prior to database lock and unblinding. The full analysis set (FAS) was used for safety analyses and includes all randomized patients who received any amount of study drug. The modified FAS (mFAS) was used for efficacy analyses and excludes patients who had negative central lab SARS-CoV-2 quantitative reverse transcriptase polymerase chain reaction at baseline.

The primary virologic endpoint was analyzed using the analysis of covariance model, and primary clinical endpoints were analyzed using either the exact method for binomial distribution or asymptotic normal approximation method, as predefined in the statistical analysis plan; details are provided in the appendix. As the trial was stopped earlier than planned (due to low enrolment prior to the surge associated with the delta variant), the sample size was smaller than anticipated and it was elected to combine the CAS+IMD dose groups and pool patients on no supplemental oxygen (phase II) and low-flow oxygen (phase III) for efficacy measures. The multiplicity adjustment approach, a hierarchical procedure, was used to control the overall type-1 error rate at 0.05 for the primary virologic and clinical outcome endpoints (**Supplementary Table 1**). Where an endpoint in the hierarchy did not reach statistical significance, all *P* values for subsequent comparisons were nominal; other analyses, including all-cause mortality, were reported descriptively.

Safety was assessed in separate analyses for patients receiving no supplemental oxygen (phase II) and low-flow oxygen (phase I/II/III). Prespecified

subgroup analyses using baseline serostatus and viral load were selected based on previous results [10]. Sample size calculations and missing data handling are described in the appendix.

Results

Demographics and Baseline Characteristics

As of April 9, 2021, 1364 patients on low-flow or no supplemental oxygen were randomized into the study, of whom 1336 were treated. Of those, 1197 (89.6%) tested positive centrally for SARS-CoV-2 (constituting the mFAS) with 406, 398, and 393 in the CAS+IMD 2.4 g, 8.0 g, and placebo groups, respectively (**Supplementary Figure 2**).

Baseline demographics were well-balanced. The median age was 62 years, 54.1% were male, mean body mass index was 31.1 kg/m², 12.1% identified as Black/African American, and 30.1% identified as Hispanic/Latino (**Table 1**). COVID-19 characteristics were similar except for a higher proportion of seropositive patients in the placebo group (51.1%) compared to the combined CAS+IMD group (45.9%; **Table 1**). The number of days of COVID-19 symptoms, viral load, and C-reactive protein concentrations at baseline were balanced, and similar proportions of patients received remdesivir and/or systemic corticosteroids (**Table 1**). Demographics and baseline characteristics by serostatus are presented in **Supplementary Table 2**.

Virologic Efficacy

CAS+IMD significantly reduced viral load in seronegative patients on low-flow or no supplemental oxygen; the least-squares (LS) mean (95% confidence interval [CI]) TWA daily change in viral load from baseline through day 7 was $-1.03 \log_{10}$ copies/mL (95% CI -1.22 to -0.84) in the placebo group compared with $-1.31 \log_{10}$ copies/mL (95% CI -1.43 to -1.18) in the CAS+IMD combined dose group, with an LS mean difference versus placebo of $-0.28 \log_{10}$ copies/mL (95% CI -0.51 to -0.05 ; $P = .0172$; **Supplementary Table 2**).

Both doses of CAS+IMD exhibited similar viral load reductions, showing improvement over placebo starting at day 3 and reaching significance at day 7, after which viral load in the CAS+IMD groups continued to fall relative to placebo (**Figure 1, Supplementary Figure 3**). The maximum LS mean differences versus placebo in seronegative patients were at day 7 (described above), day 9 ($-0.47 \log_{10}$ copies/mL, 95% CI -0.71 to -0.23), and day 11 ($-0.59 \log_{10}$ copies/mL, 95% CI -0.85 to -0.34 ; **Figure 1A**). The overall population LS mean fell below the lower limit of quantification ($2.85 \log_{10}$ copies/mL) 2 days earlier with CAS+IMD (day 9 CAS+IMD vs day 11 placebo; **Supplementary Figure 3**). Reductions of viral load were observed in the seronegative (**Figure 1A**) and the overall populations (**Supplementary Figure 3**), with greater reductions in seronegative patients.

Clinical Efficacy

Death or Mechanical Ventilation

Endpoints were examined both from days 1 to 29 and days 6 to 29, and were evaluated in the seronegative, high-viral load, and overall populations, as described in the Methods. The analyses presented herein examine the pooled CAS+IMD dose group and pooled cohorts for low-flow and no supplemental oxygen (**Figure 2**). Individual dose groups of 2.4 g and 8.0 g of CAS+IMD (**Supplementary Figure S4**) and separate cohorts by respiratory status (**Supplementary Figure S5**) were also examined, and showed trends of benefit in seronegative patients across all clinical endpoints.

In the statistical hierarchy (**Supplementary Table 1**), the first test for clinical efficacy on the endpoint of death or mechanical ventilation in the high viral load population from days 6 to 29 showed a numerically lower risk compared to placebo

but did not reach statistical significance (relative risk reduction [RRR], 25.5%; 95% CI -16.2–52.2; $P = .2048$; **Table 2**); accordingly, all subsequent clinical efficacy analyses are considered descriptive, with nominal P values. The second test for clinical efficacy on the endpoint of death or mechanical ventilation in the seronegative population from days 6 to 29 showed an RRR of 47.1% (95% CI 10.2–68.8; nominal $P = .0195$ **Table 2**). Trends of improvement were also observed from days 6 to 29 in the overall population (RRR, 24.2%; 95% CI -10.9–48.2; nominal $P = .1486$; **Table 2**).

Treatment with CAS+IMD led to a reduction in the proportions of patients who died or required mechanical ventilation, with improvement from days 1 to 29 in the high viral load (RRR, 35.0%; 95% CI 6.6–54.8, nominal $P = .0249$), seronegative (RRR, 47.0%; 95% CI 17.7–65.8; nominal $P = .0061$), and overall (RRR, 30.9%; 95% CI 5.4–49.5; nominal $P = .0212$) populations (**Table 2**). While seronegative patients exhibited the greatest benefit from CAS+IMD treatment, no meaningful benefit or harm was observed in seropositive patients (RRR, 19.5%; 95% CI -32.8–51.2; nominal $P = .3010$; **Figure 2**).

All-Cause Mortality

Treatment with CAS+IMD led to numeric improvement in all-cause mortality through day 29 in the seronegative, high-viral load, and overall populations. The greatest reduction in the relative risk of death occurred in seronegative patients; 24/360 (6.7%) died within 28 days in the CAS+IMD group, compared to 24/160 (15.0%) in the placebo group (RRR, 55.6%; 95% CI 24.2–74.0; nominal $P = .0032$; **Figure 2B**). No harm or meaningful benefit was observed in the seropositive population (**Figure 2A**). For the overall population, driven by the seronegative group, a substantial

reduction in death was observed in which 59/804 patients (7.3%) died within 28 days in the CAS+IMD combined dose group, compared to 45/393 patients (11.5%) in the placebo group (RRR, 35.9%; 95% CI 7.3–55.7; nominal $P = .0178$; **Figure 2B**). The improvement in all-cause mortality with CAS+IMD persisted through study day 57 (**Supplementary Figure 6**). Similar results were also observed in the secondary endpoints of hospital discharge and readmission, shown in **Supplementary Table 3** and **Supplementary Table 4**, and described in the appendix.

Safety

SAEs were experienced by more patients in the placebo group than the CAS+IMD group for patients on low-flow oxygen (131/469 [27.9%] placebo vs 224/941 [23.8%] CAS+IMD) and no supplemental oxygen (43/198 [21.7%] placebo vs 61/399 [15.3%] CAS+IMD; **Table 3**). More patients experienced treatment-emergent adverse events that resulted in death in the placebo group compared with CAS+IMD for patients on low-flow oxygen (72/469 [15.4%] placebo vs 108/941 [11.5%] CAS+IMD **Supplementary Table 5**) and no supplemental oxygen (15/198 [7.6%] placebo vs 15/399 [3.8%] CAS+IMD **Supplementary Table 6**), consistent with the treatment benefit of CAS+IMD. These events were generally considered by the sponsor as associated with COVID-19 and its complications.

Grade ≥ 2 IRRs occurred in few patients on low-flow (5/469 [1.1%] placebo vs 18/941 [1.9%] CAS+IMD) and no supplemental oxygen (1/198 [0.5%] placebo vs 8/399 [2.0%] CAS+IMD; **Table 3**). Grade ≥ 2 hypersensitivity reactions also occurred in few patients on low-flow (1/469 [0.2%] placebo vs 7/941 [0.7%] CAS+IMD) and no supplemental oxygen (1/198 [0.5%] placebo vs 2/399 [0.5%] CAS+IMD **Table 3**). AEs are further detailed in **Supplementary Table 7** and **Supplementary Table 8**.

Discussion

Hospitalized patients with COVID-19 experience high mortality rates, ranging from 10% to 30% [4, 14-16]. As CAS+IMD is a potent antiviral monoclonal antibody combination shown to rapidly reduce SARS-CoV-2 viral load and modulate a patient's disease course across various populations [8-11], it was prospectively hypothesized that reducing viral burden as early as possible would decrease morbidity and mortality associated with SARS-CoV-2 hospitalization. Until the recently released results from the RECOVERY platform trial [17], it was unknown whether reducing viral burden in patients who were already hospitalized would be early enough to meaningfully impact clinical outcomes. RECOVERY reported a 20% reduction in 28-day mortality with CAS+IMD treatment compared to standard of care in seronegative patients. The current placebo-controlled randomized trial (with approximately half of patients receiving concomitant remdesivir) demonstrated and extended the benefit preliminarily reported in the RECOVERY trial among seronegative patients, and also documented no harm signals among seropositive patients. When added to standard-of-care treatment, CAS+IMD significantly reduced all-cause mortality for patients on low-flow or no supplemental oxygen. While the primary clinical endpoint, which had a strong positive trend, did not reach significance, all clinical endpoints demonstrated substantial numeric improvements, predominantly driven by the robust and nominally significant results in the seronegative population. In addition, CAS+IMD improved the rates of hospital discharge and death or readmission to hospital at day 29, which persisted through day 57, showing direct benefit to patients as well as the overburdened healthcare system, particularly in the context of viral variants such as delta, which doubles the risk of hospitalization [18].

The clinical benefits observed in the overall population of this study, including improvements in death or mechanical ventilation, all-cause mortality, and discharge from hospital, were driven by seronegative patients, but no harm was demonstrated in seropositive patients, for whom there were numerically fewer deaths through day 29 with CAS+IMD compared to placebo. In the current variant-rich world with widespread COVID-19 vaccination, the utility of serostatus is unclear; numerous publications cite that even vaccinated patients with high antibody titers may have little to no neutralizing activity to emerging variants [19-22]. Given this context, the results from this study may support the use of CAS+IMD in hospitalized patients with COVID-19, regardless of serostatus. Future studies are needed to further explore the potential clinical benefit in seropositive patients.

CAS+IMD is the first monoclonal antibody therapy, and the first SARS-CoV-2 antiviral, that significantly lowers viral load and reduces mortality in hospitalized patients with COVID-19. Very few treatments have demonstrated a mortality benefit in hospitalized COVID-19 patients. Most of these treatments are designed to modulate the immune response late in the disease course after damage has occurred, rather than to clear SARS-CoV-2. The corticosteroid dexamethasone showed a 17% improvement in 28-day mortality in the RECOVERY trial, with the greatest benefit in patients receiving mechanical ventilation [17]. Baricitinib, a Janus kinase inhibitor, improved 28-day mortality by 38% in hospitalized patients [23]. Recently, interleukin-6 inhibitors such as tocilizumab and sarilumab were recommended by the World Health Organization for use in hospitalized patients, in whom they reduced mortality by 13% [24, 25]. The Food and Drug Administration-approved medication remdesivir has shown neither a reduction in viral load nor a mortality benefit in hospitalized patients [26]. CAS+IMD's mechanism of action and

safety profile should allow combination approaches with any or all of these other agents.

The safety profile of CAS+IMD in patients on low-flow or no supplemental oxygen was consistent with that observed previously in outpatients and hospitalized patients with COVID-19 [10, 13], showing low rates of infusion-related and hypersensitivity reactions, as expected for a fully human antibody against an exogenous target. Overall, CAS+IMD was well tolerated. The placebo group experienced a greater frequency of SAEs and adverse events leading to death than the CAS+IMD group, consistent with the clinical benefit of treatment.

The respiratory status of the population in this manuscript includes those receiving low-flow or no supplemental oxygen, as the study did not enroll sufficient numbers of patients on high-intensity oxygen or mechanical ventilation prior to pausing of these cohorts due to an imbalance in mortality observed in interim data early during the conduct of the study, which was not observed in the much larger RECOVERY trial [17]. The absence of full representation across the spectrum of hospitalized patients on varying degrees of oxygen support is a limitation of this study. Additionally, this study was prematurely terminated due to slow recruitment prior to the surge associated with the emergence of the delta variant, and was thus also conducted before the recent B.1.1.529 (omicron) variant began circulating. CAS+IMD, which contains 2 distinct neutralizing antibodies [27, 28], has been shown to have diminished neutralization against the omicron variant [29], but retains neutralizing potency against several viral variants of concern, including B.1.1.7 (alpha), B.1.351 (beta), B.1.617.2 (delta), B.1.429 (epsilon), and P.1 (gamma) [30]. Nonetheless, the results of this trial are informative for circulating variants

susceptible to CAS+IMD and could be applicable for the evaluation of future antibodies in the hospitalized population.

As a result of the smaller sample size, key analyses pooled the 2 patient cohorts as well as the 2 doses. Sensitivity analyses did not reveal major efficacy differences across the cohorts or doses; minor variability in the magnitude of risk reductions, with greater effects for the 2.4 g dose compared to the 8.0 g dose, was likely due to small numbers within each group suggesting that either dose can be utilized in hospitalized individuals requiring low-flow or no supplemental oxygen. Overall, trends for treatment benefit on mortality and other efficacy endpoints extend the observations in the larger RECOVERY trial, where benefit was seen in all patients regardless of respiratory status.

Authorized options for intervention with a monoclonal antibody anti-viral treatment have been restricted to outpatients with COVID-19 or as post-exposure prophylaxis [5-7]. Taken together with reports from the RECOVERY trial, these data support CAS+IMD representing a well-tolerated treatment option to reduce the risk of mortality in hospitalized COVID-19 patients and across the disease continuum of SARS-CoV-2, from prevention to hospitalization.

Funding

This work was supported by Regeneron Pharmaceuticals, Inc. Certain aspects of this project were supported by federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority, under OT number HHSO100201700020C.

Potential conflicts of interest

S. S-K., S. A., Y. Sun, R. B., J. Mei, J. Miller, C. P., V. P., Y. Z., A. M., J. D. D., Y. K., A. C., B. K., Y. Soo, A. T.D., G. P. G., L. L., N. B., and D. M. W. are Regeneron Pharmaceuticals, Inc. employees/stockholders and report grants from BARDA. E. M. reports payments to his institution received from NIH/NIAID, NIH/NIGMS, SciClone Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Pfizer, Chemic Labs/KODA Therapeutics, Cidara, and Leidos Biomedical Research Inc./NCI. V. P. M. and J. C. W. report grants from BARDA. S. S. is an Excision BioTherapeutics employee/stockholder and former Regeneron Pharmaceuticals, Inc. employee and current stockholder, and reports grants from BARDA. L. C. is a Regeneron Pharmaceuticals, Inc. employee and reports grants from BARDA. A. T. H. is a Regeneron Pharmaceuticals, Inc. employee/stockholder, a former Pfizer employee and current stockholder, has a patent pending with Regeneron Pharmaceuticals, Inc., and reports grants from BARDA. J. D. H., K. C. T., and G. A. H. are Regeneron Pharmaceuticals, Inc. employees/stockholders and have a patent pending, which has been licensed and receiving royalties, with Regeneron Pharmaceuticals, Inc. R. H. is a former Regeneron employee and current stockholder, and reports grants from BARDA. N. S. and G. D. Y. are Regeneron Pharmaceuticals, Inc. employees/stockholders have issued patents (U.S. Patent Nos. 10,787,501,

10,954,289, and 10,975,139) and pending patents, which have been licensed and receiving royalties, with Regeneron Pharmaceuticals, Inc., and reports grants from BARDA.

Data sharing

Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymised participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to <https://vivli.org/>.

Acknowledgements

We thank the patients who participated in this study, as well as their families; the study investigators; the members of the IDMC; Kaitlyn Scacalossi, PhD, and Caryn Trbovic, PhD, from Regeneron Pharmaceuticals for assistance with development of the manuscript; and Prime, Knutsford, UK, for formatting and copyediting suggestions.

References

1. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. *N Engl J Med*, **2020**; 382: 2372-2374.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*, **2020**; 382: 1708-1720.
3. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. *JAMA*, **2020**; 324: 460-470.
4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA*, **2020**; 323: 2052-2059.
5. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. **2021**.
6. Food and Drug Administration. FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19>. Accessed August 25, 2021.
7. Regeneron Pharmaceuticals Inc. UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection. Available at:

<https://newsroom.regeneron.com/news-releases/news-release-details/uk-authorizes-regeneron-antibody-cocktail-prevent-and-treat#:~:text=As%20part%20of%20the%20MHRA,respond%20to%20or%20be%20protected>. Accessed November 3, 2021.

8. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. *N Engl J Med*, **2021**; 384: 238-251.
9. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination for Covid-19 prevention. *medRxiv*, **2021**; 2021.2006.2014.21258567.
10. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. *N Engl J Med*, **2021**; 385: e81.
11. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. *N Engl J Med*, **2021**; 385: 1184-1195.
12. Verderese JP, Stepanova M, Lam B, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID-19: A real-world experience. *Clin Infect Dis [Preprint]*. [cited June 24, 2021]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/34166513>.

13. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv, **2021**; 2021.2006.2015.21258542.
14. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, **2020**; 369: m1985.
15. Rieg S, von Cube M, Kalbhenn J, et al. COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany. PLoS One, **2020**; 15: e0242127.
16. Finelli L, Gupta V, Petigara T, Yu K, Bauer KA, Puzniak LA. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw Open, **2021**; 4: e216556.
17. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med, **2021**; 384: 693-704.
18. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis, **2021**; 22: 35-42.

19. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*, **2021**; 596: 276-280.
20. Chen X, Chen Z, Azman AS, et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. *Clin Infect Dis* [Preprint]. [cited July 24, 2021]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/34302458>.
21. Shastri J, Parikh S, Aggarwal V, et al. Severe SARS-CoV-2 breakthrough reinfection with Delta variant after recovery from breakthrough infection by Alpha variant in a fully vaccinated health worker. *Front Med (Lausanne)*, **2021**; 8: 737007.
22. Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Al Mutair A. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. *Hum Vaccin Immunother*, **2021**; 17: 3491-3494.
23. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med*, **2021**; 9: 1407-1418.
24. World Health Organization. WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access. Available at: <https://www.who.int/news/item/06-07-2021-who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and->

[urges-producers-to-join-efforts-to-rapidly-increase-access](#). Accessed September 29, 2021.

25. Rosas IO, Brau N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. *N Engl J Med*, **2021**; 384: 1503-1516.
26. Ohl ME, Miller DR, Lund BC, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. *JAMA Netw Open*, **2021**; 4: e2114741.
27. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science*, **2020**; 369: 1014-1018.
28. Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science*, **2020**; 369: 1010-1014.
29. Regeneron Pharmaceuticals Inc. Regeneron's Next Generation Monoclonal Antibodies are Active Against All Known Variants of Concern, Including Both Omicron and Delta. Available at: <https://investor.regeneron.com/static-files/4aed42a1-3d26-48af-bd01-3f0c92938c11>. Accessed January 6, 2022.
30. Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. *Cell*, **2021**; 184: 3949-3961 e3911.

Table 1. Demographics and baseline characteristics^a

	Placebo (n = 393)	CAS+IMD 2.4 g IV (n = 406)	CAS+IMD 8.0 g IV (n = 398)	CAS+IMD combined doses (n = 804)	Total (N = 1197)
Age, years					
Median (range)	64.0 (20:97)	60.0 (20:97)	62.0 (20:98)	61.0 (20:100)	62.0 (20:100)
≥65	191 (48.6%)	164 (40.4%)	170 (42.7%)	334 (41.5%)	525 (43.9%)
Male sex	210 (53.4%)	221 (54.4%)	216 (54.3%)	437 (54.4%)	647 (54.1%)
Race					
	239 (60.8%)	246 (60.6%)	264 (66.3%)	510 (63.4%)	749 (62.6%)
White	46 (11.7%)	57 (14.0%)	42 (10.6%)	99 (12.3%)	145 (12.1%)
Black or African American	16 (4.1%)	17 (4.2%)	14 (3.5%)	31 (3.9%)	47 (3.9%)
Asian	9 (2.3%)	9 (2.2%)	13 (3.3%)	22 (2.7%)	31 (2.6%)
American Indian or Alaska Native	0 (0%)	1 (0.2%)	2 (0.5%)	3 (0.4%)	3 (0.3%)
Native Hawaiian or Pacific Islander	26 (6.6%)	28 (6.9%)	22 (5.5%)	50 (6.2%)	76 (6.3%)
Unknown	57 (14.5%)	48 (11.8%)	41 (10.3%)	89 (11.1%)	146 (12.2%)
Not reported	239 (60.8%)	246 (60.6%)	264 (66.3%)	510 (63.4%)	749 (62.6%)
Ethnicity					
Hispanic or Latino	115 (29.3%)	137 (33.7%)	108 (27.1%)	245 (30.5%)	360 (30.1%)
Not Hispanic or Latino	260 (66.2%)	251 (61.8%)	269 (67.6%)	520 (64.7%)	780 (65.2%)
Not reported	18 (4.6%)	18 (4.4%)	21 (5.3%)	39 (4.9%)	57 (4.8%)
Mean weight, kg	87.0±23.4	89.0±24.9	89.0±24.6	89.0±24.7	88.3±24.3
Body-mass index ^b					
Mean	30.8±7.5	31.2±7.9	31.2±8.2	31.2±8.1	31.1±7.9
≥30	186 (47.3%)	192 (47.3%)	190 (47.7%)	382 (47.5%)	568 (47.5%)
Median days COVID-19 illness prior to baseline (Q1:Q3)	5.0 (4.0:8.0)	6.0 (4.0:8.0)	6.0 (4.0:8.0)	6.0 (4.0:8.0)	6.0 (4.0:8.0)
Baseline viral load					
Median (Q1:Q3), log ₁₀ copies/mL	6.3 (5.0:7.6)	6.4 (5.1:7.6)	6.5 (5.3:7.8)	6.4 (5.1:7.7)	6.4 (5.1:7.7)
>10 ⁴ copies/mL	356 (90.6%)	366 (90.1%)	359 (90.2%)	725 (90.2%)	1081 (90.3%)

>10 ⁶ copies/mL	229 (58.3%)	231 (56.9%)	236 (59.3%)	467 (58.1%)	696 (58.1%)
Baseline serology status					
Negative	160 (40.7%)	172 (42.4%)	188 (47.2%)	360 (44.8%)	520 (43.4%)
Positive	201 (51.1%)	191 (47.0%)	178 (44.7%)	369 (45.9%)	570 (47.6%)
Other (not determined, borderline)	32 (8.1%)	43 (10.6%)	32 (8.0%)	75 (9.3%)	107 (8.9%)
Presence of neutralizing antibodies for seropositive patients, n/N					
Positive	140/201 (69.7%)	140/191 (73.3%)	129/178 (72.5%)	269/369 (72.9%)	409/570 (71.8%)
Negative	35/201 (17.4%)	30/191 (15.7%)	31/178 (17.4%)	61/369 (16.5%)	96/570 (16.8%)
Borderline	15/201 (7.5%)	10/191 (5.2%)	8/178 (4.5%)	18/369 (4.9%)	33/570 (5.8%)
Unknown/missing/indeterminate	11/201 (5.5%)	11/191 (5.8%)	10/178 (5.6%)	21/369 (5.7%)	32/570 (5.6%)
Mean C-reactive protein, mg/L	75.1±68.6	73.9±96.7	71.1±84.5	72.5±91.0	73.4±84.3
Mean neutrophil-lymphocyte ratio	5.9±5.7	2.3±2.1	8.0±4.3	5.6±4.5	5.7±4.9
Concomitant medications					
Remdesivir	220 (56.0%)	212 (52.2%)	225 (56.5%)	437 (54.4%)	657 (54.9%)
Systemic corticosteroids	294 (74.8%)	294 (72.4%)	307 (77.1%)	601 (74.8%)	895 (74.8%)
Use of supplemental oxygen					
Non-invasive ventilation or high-flow oxygen devices	1 (0.4%)	0	0	0	1 (0.1%)
Supplemental oxygen [‡]	225 (99.6%)	223 (100%)	223 (100%)	446 (100%)	671 (99.9%)
Immunocompromised	85 (21.6%)	87 (21.4%)	85 (21.4%)	172 (21.4%)	257 (21.5%)

Data are n (%), mean ±SD, or median (range).

Abbreviations; CAS+IMD, casirivimab and imdevimab; COVID-19, coronavirus disease 2019; IV, intravenous; SD, standard deviation.

[‡]Modified full analysis set presented; plus-minus values are means ±SD.

^bThe body-mass index is the weight in kilograms divided by the square of the height in meters.

^cNot requiring high-flow oxygen devices.

Table 2. Primary virologic and clinical endpoints

Hierarchy	Endpoint	Placebo	CAS+IMD 2.4 g IV	CAS+IMD 8.0 g IV	CAS+IMD combined
Primary virologic outcome^{a,b}					
1.	Time-weighted average change in viral load from baseline (day 1) to day 7 in seronegative mFAS				
	Patients, n	131	150	160	310
	LS mean change (SE), log ₁₀ copies/mL	-1.03 (0.10)	-1.28 (0.09)	-1.34 (0.09)	-1.31 (0.06)
	95% CI	-1.22 to -0.84	-1.46 to -1.10	-1.51 to -1.16	-1.43 to -1.18
	Difference versus placebo at day 7, log ₁₀ copies/mL				
	LS mean (SE)	-	-0.25 (0.13)	-0.31 (0.13)	-0.28 (0.12)
	95% CI	-	-0.51 to 0.02	-0.57 to 0.05	-0.51 to 0.05
	<i>P</i> value	-	0.0663	0.0204	0.0172
Primary clinical outcome^{a,c,d}					
2.	Proportion of patients who died or went on mechanical ventilation from day 6 to day 29 in high-viral load mFAS				
	N/total n	28/211 (13.3%)	16/220 (7.3%)	28/225 (12.4%)	44/445 (9.9%)
	Relative risk reduction, %	-	45.2	6.2	25.5
	95% CI, %	-	1.7 to 69.5	-52.9 to 42.5	-16.2 to 52.2
	<i>P</i> value	-	0.0431	0.7975	0.2048
3.	Proportion of patients who died or went on mechanical ventilation from day 6 to day 29 in seronegative mFAS				
	N/total n	22/147 (15.0%)	8/162 (4.9%)	19/179 (10.6%)	27/341 (7.9%)
	Relative risk reduction, %	-	67.0	29.1	47.1%
	95% CI, %	-	28.2 to	-25.9 to	10.2 to

		84.8	60.0	68.8	
	<i>P</i> value ^e	-	0.0039	0.2415	0.0195
4.	Proportion of patients who died or went on mechanical ventilation from day 6 to day 29 in overall mFAS				
	N/total n	39/367 (10.6%)	21/387 (5.4%)	41/383 (10.7%)	62/770 (8.1%)
	Relative risk reduction, %	-	48.9	-0.7	24.2
	95% CI, %	-	14.9 to 69.4	-52.5 to 33.4	-10.9 to 48.2
	<i>P</i> value ^e	-	0.0085	0.9902	0.1486
5.	Proportion of patients who died or went on mechanical ventilation from day 1 to day 29 in high-viral load mFAS				
	N/total n	43/229 (18.8%)	23/231 (10.0%)	34/236 (14.4%)	57/467 (12.2%)
	Relative risk reduction, %	-	47.0	23.3	35.0
	95% CI, %	-	15.0 to 66.9	-15.8 to 49.2	6.6 to 54.8
	<i>P</i> value ^e	-	0.0092	0.2210	0.0249
6.	Proportion of patients who died or went on mechanical ventilation from day 1 to day 29 in seronegative mFAS				
	N/total n	31/160 (19.4%)	14/172 (8.1%)	23/188 (12.2%)	37/360 (10.3%)
	Relative risk reduction, %	-	58.0	36.9	47.0
	95% CI, %	-	24.0 to 76.8	-3.7 to 61.6	17.7 to 65.8
	<i>P</i> value ^e	-	0.0045	0.0714	0.0061
7.	Proportion of patients who died or went on mechanical ventilation from day 1 to day 29 in overall mFAS				
	N/total n	58/393 (14.8%)	32/406 (7.9%)	50/398 (12.6%)	82/804 (10.2%)
	Relative risk reduction, %	-	46.6	14.9	30.9
	95% CI, %	-	19.6 to 64.5	-21.0 to 40.1	5.4 to 49.5

<i>P</i> value ^e	-	0.0023	0.3544	0.0212
-----------------------------	---	--------	--------	--------

Abbreviations: CAS+IMD, casirivimab and imdevimab; CI, confidence interval; IV, intravenous; LS, least squares; mFAS, modified full analysis set.

^aPooled phase III cohort 1 and phase II cohort 1A.

^bLS mean, 95% CI, and *P* value for change from baseline on log scale for each treatment group is based on the analysis of covariance model with treatment group and the type of background standard of care (antiviral therapies and non-antiviral therapies) as fixed effects, and baseline viral load and treatment baseline as covariates. Negative changes imply improvement in viral load.

^c95% CI for the relative risk and relative risk reduction (1 – relative risk) uses the Farrington-Manning method.

^d*P* value is derived from the Cochran-Mantel-Haenszel test stratified by the type of background standard of care (antiviral therapies and non-antiviral therapies). If $n_p \leq 5$ or $n(1-p) \leq 5$ in any treatment group, *P* value is based on Fisher's exact test. Nominally significant *P* values were omitted.

^e*P* value is considered nominal in statistical hierarchy

Table 3. Overview of treatment-emergent adverse events

	Placebo	CAS+IMD 2.4 g IV	CAS+IMD 8.0 g IV	CAS+IMD combined
Low-flow oxygen^a	n = 469	n = 470	n = 471	n = 941
Patients with any TEAE ^b	132 (28.1%)	118 (25.1%)	131 (27.8%)	249 (26.5%)
Patients with any grade 3 or 4 TEAE	93 (19.8%)	68 (14.5%)	82 (17.4%)	150 (15.9%)
Patients with any treatment-emergent SAE	131 (27.9%)	106 (22.6%)	118 (25.1%)	224 (23.8%)
Patients with any treatment-emergent AESI	6 (1.3%)	10 (2.1%)	14 (3.0%)	24 (2.6%)
Patients with any treatment-emergent serious AESI	2 (0.4%)	4 (0.9%)	6 (1.3%)	10 (1.1%)
Patients with any treatment-emergent AESI of infusion-related reactions (grade ≥ 2) through day 4 ^c	5 (1.1%)	7 (1.5%)	11 (2.3%)	18 (1.9%)
Patients with any treatment-emergent AESI of hypersensitivity reactions (grade ≥ 2) through day 29	1 (0.2%)	3 (0.6%)	4 (0.8%)	7 (0.7%)
Patients with any TEAE leading to study infusion interruption	1 (0.2%)	1 (0.2%)	1 (0.2%)	2 (0.2%)
No supplemental oxygen^d	n = 198	n = 202	n = 197	n = 399
Patients with any TEAE ^b	48 (24.2%)	31 (15.3%)	37 (18.8%)	68 (17.0%)
Patients with any grade 3 or 4 TEAE	31 (15.7%)	24 (11.9%)	23 (11.7%)	47 (11.8%)
Patients with any treatment-emergent SAE	43 (21.7%)	29 (14.4%)	32 (16.2%)	61 (15.3%)
Patients with any treatment-emergent AESI	2 (1.0%)	4 (2.0%)	6 (3.0%)	10 (2.5%)
Patients with any treatment-emergent serious AESI	1 (0.5%)	1 (0.5%)	3 (1.5%)	4 (1.0%)
Patients with any treatment-emergent AESI of infusion-related reactions (grade ≥ 2) through day 4 ^c	1 (0.5%)	4 (2.0%)	4 (2.0%)	8 (2.0%)
Patients with any treatment-emergent AESI of hypersensitivity reactions (grade ≥ 2) through day	1 (0.5%)	0	2 (1.0%)	2 (0.5%)

29

Patients with any TEAE leading to study infusion interruption	0	0	2 (1.0%)	2 (0.5%)
---	---	---	----------	----------

Data are n (%).

Abbreviations: AESI, adverse event of special interest; CAS+IMD, casirivimab and imdevimab; IV, intravenous; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

^aPhase I/II/III cohort 1.

^bTEAEs collected include treatment-emergent SAEs, AESIs, and grade 3/4 TEAEs, as well as ad-hoc/voluntarily reported TEAEs by some sites.

^cDeemed treatment-related as per investigator assessment.

^dPhase II cohort 1A.

Figure 1. Viral Load by Serostatus

Panel A graph shows LS mean viral load following administration of CAS+IMD (2.4 g, 8.0 g, or combined analysis of 2.4 and 8.0 g) or placebo for patients who tested negative for all SARS-CoV-2 antibodies at baseline (seronegative). Panel B shows the same but for patients who tested positive for any SARS-CoV-2 antibody at baseline (seropositive). For both panels, the lower limit of quantification is 2.85 log₁₀ copies/mL.

Abbreviations: CAS+IMD, casirivimab and imdevimab; CI, confidence interval; IV, intravenous; mFAS, modified full analysis set; LS, least-squares; PBO, placebo; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SE, standard error; TWA, time-weighted average.

Figure 2. Efficacy Outcomes by Serostatus for Combined Dose CAS+IMD from Day 1 though Day 29

Panel A shows a Kaplan–Meier curve for the proportion of patients who died through study day 29, after administration of CAS+IMD (combined analysis of 2.4 g or 8.0 g) or placebo. Results are analyzed separately for patients who were seronegative or seropositive at baseline. + indicates censoring. Panel B shows a forest plot of relative risk and relative risk reduction with 95% CIs for CAS+IMD combined dose analysis (2.4 g and 8.0 g) versus placebo. Parameters examined include death within 28 days, discharge alive from hospital from days 1 to 29, and death or mechanical ventilation from days 1 to 29. For all populations, the mFAS was comprised of patients who tested positive for SARS-CoV-2 at baseline. Populations analyzed include patients who tested negative for all SARS-CoV-2 antibodies at baseline (seronegative mFAS), patients who tested positive for any SARS-CoV-2 antibody at baseline (seropositive mFAS), those with inconclusive or missing baseline serology (other), and the overall population regardless of serostatus (overall mFAS). For the proportion of death within 28 days and the proportion of death or mechanical ventilation with 28 days, the lower bounds of the CI of the relative risk reduction were –342.0% and –241.0%, respectively, which are presented as “NA” in the figure. *P* values are considered nominal.

Abbreviations: CAS+IMD, casirivimab and imdevimab; CI, confidence interval; mFAS, modified full analysis set; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure 1. Viral Load by Serostatus


A. —●— Placebo —▲— REGEN-COV 2.4 g IV —■— REGEN-COV 8.0 g IV —◆— REGEN-COV combined

medRxiv preprint doi: <https://doi.org/10.1101/2021.11.05.81265688>; this version posted January 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

Seronegative mFAS

TWA change from baseline, LS mean (95% CI)

	Placebo (N=160)	2.4 g (N=172)	8.0 g (N=188)	Combined (N=360)	2.4 g (N=172)	8.0 g (N=188)	Combined (N=360)
Day 3	-0.45 (-0.60, -0.30)	-0.48 (-0.62, -0.35)	-0.59 (-0.73, -0.46)	-0.54 (-0.64, -0.45)	-0.03 (-0.24, 0.17)	-0.15 (-0.35, 0.05)	-0.10 (-0.27, 0.08)
Day 5	-0.82 (-1.00, -0.63)	-0.89 (-1.06, -0.71)	-0.95 (-1.12, -0.78)	-0.92 (-1.04, -0.80)	-0.07 (-0.32, 0.18)	-0.13 (-0.38, 0.11)	-0.10 (-0.32, 0.12)
Day 7	-1.03 (-1.22, -0.84)	-1.28 (-1.46, -1.10)	-1.34 (-1.51, -1.16)	-1.31 (-1.43, -1.18)	-0.25 (-0.51, 0.02)	-0.31 (-0.57, -0.05)	-0.28 (-0.51, -0.05)
Day 9	-1.22 (-1.42, -1.02)	-1.67 (-1.87, -1.48)	-1.70 (-1.88, -1.51)	-1.69 (-1.82, -1.56)	-0.45 (-0.73, -0.17)	-0.48 (-0.75, -0.20)	-0.47 (-0.71, -0.23)
Day 11	-1.39 (-1.60, -1.17)	-1.97 (-2.17, -1.76)	-2.00 (-2.20, -1.80)	-1.98 (-2.12, -1.84)	-0.58 (-0.87, -0.28)	-0.61 (-0.90, -0.32)	-0.59 (-0.85, -0.34)
Day 13	-1.61 (-1.84, -1.38)	-2.23 (-2.44, -2.01)	-2.29 (-2.50, -2.08)	-2.26 (-2.41, -2.11)	-0.62 (-0.93, -0.30)	-0.68 (-0.99, -0.37)	-0.65 (-0.92, -0.38)



B. —●— Placebo —▲— REGEN-COV 2.4 g IV —■— REGEN-COV 8.0 g IV —◆— REGEN-COV combined

medRxiv preprint doi: <https://doi.org/10.1101/2021.11.05.21265856>; this version posted January 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Seropositive mFAS

LS mean (95% CI) available under a CC-BY-NC-ND 4.0 International license

	Placebo (N=201)	2.4 g (N=172)	8.0 g (N=188)	Combined (N=360)	2.4 g (N=172)	8.0 g (N=188)	Combined (N=360)
Day 3	-0.44 (-0.58, -0.31)	-0.61 (-0.76, -0.46)	-0.56 (-0.71, -0.42)	-0.59 (-0.69, -0.48)	-0.17 (-0.37, 0.03)	-0.12 (-0.32, 0.08)	-0.14 (-0.32, 0.03)
Day 5	-0.74 (-0.90, -0.59)	-0.95 (-1.11, -0.78)	-0.85 (-1.02, -0.68)	-0.90 (-1.02, -0.78)	-0.20 (-0.43, 0.02)	-0.11 (-0.33, 0.12)	-0.16 (-0.35, 0.03)
Day 7	-0.96 (-1.11, -0.80)	-1.19 (-1.36, -1.03)	-1.14 (-1.31, -0.97)	-1.17 (-1.29, -1.05)	-0.24 (-0.46, -0.01)	-0.18 (-0.41, 0.05)	-0.21 (-0.41, -0.02)
Day 9	-1.22 (-1.39, -1.05)	-1.45 (-1.62, -1.27)	-1.39 (-1.57, -1.21)	-1.42 (-1.55, -1.30)	-0.23 (-0.47, 0.01)	-0.17 (-0.42, 0.07)	-0.20 (-0.41, 0.00)
Day 11	-1.42 (-1.60, -1.25)	-1.62 (-1.80, -1.44)	-1.55 (-1.74, -1.36)	-1.59 (-1.72, -1.46)	-0.20 (-0.45, 0.05)	-0.13 (-0.38, 0.13)	-0.17 (-0.38, 0.05)
Day 13	-1.62 (-1.80, -1.44)	-1.78 (-1.97, -1.59)	-1.73 (-1.93, -1.54)	-1.76 (-1.90, -1.62)	-0.16 (-0.43, 0.10)	-0.12 (-0.38, 0.15)	-0.14 (-0.37, 0.09)





Figure 2. Efficacy Outcomes by Serostatus for Combined Dose REGEN-COV from Day 1 though Day 29

A. Mortality through study day 29



No. at Risk	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28
Seronegative placebo	160	159	159	158	157	153	151	150	147	146	144	143	143	140	138	137	135	132	132	132	131	129	127	127	126	125	124	123	121
Seronegative REGEN-COV combined	360	358	356	353	352	348	346	343	341	338	333	331	329	325	324	324	324	323	320	316	314	313	312	311	310	310	310	308	308
Seropositive placebo	201	201	201	199	197	196	195	193	192	191	191	188	187	186	186	185	183	179	178	177	177	177	175	175	174	174	174	174	174
Seropositive REGEN-COV combined	369	367	367	364	364	364	362	357	353	349	347	345	342	340	339	336	336	336	336	335	332	329	328	327	325	324	324	324	324

B.

Relative Risk and Relative Risk Reduction from Day 1 through Day 29

